Cesaro P, Fenelon G, Remy P
Clinique neurologique, département de neurosciences cliniques, CHU Henri-Mondor, 51, avenue du Maréchal-De-Lattre-de-Tassigny, 94000 Créteil, France.
Rev Neurol (Paris). 2009 Nov;165(11):857-62. doi: 10.1016/j.neurol.2009.03.017. Epub 2009 May 31.
In the last years, several experimental biotherapies have been developed to treat Parkinson's disease. Initially, fetal dopaminergic transplants were proposed. Although a proof of concept and encouraging results have been provided, limitations of this treatment emerged over the years and the failure of controlled trials have conducted to a pause in the development of strategies based on fetal cells. Alternative approaches such as the use of retinal pigmented cells recently provided disappointing results in patients and much hope has now been reported on other sources of dopaminergic neurons such as those originating from stem cells. This strategy is however not yet ready for clinical trials in patients. Eventually, gene therapy is a new original experimental technique which has elicited several trials in the last few years some of them being promising.
在过去几年中,已经开发了几种用于治疗帕金森病的实验性生物疗法。最初,有人提出进行胎儿多巴胺能移植。尽管已经提供了概念验证和令人鼓舞的结果,但多年来这种治疗方法的局限性逐渐显现,并且对照试验的失败导致基于胎儿细胞的治疗策略的开发暂停。诸如使用视网膜色素细胞等替代方法最近在患者中取得了令人失望的结果,现在人们对其他多巴胺能神经元来源(如源自干细胞的神经元)寄予了很大希望。然而,这种策略尚未准备好用于患者的临床试验。最终,基因治疗是一种新的原创性实验技术,在过去几年中引发了多项试验,其中一些试验前景良好。